In the early 1950s, notable figures in science, philosophy, culture, and politics—such as Albert Einstein, Carl Jung, and Graham Greene—were part of an initiative called “outsights” aimed at exploring powerful psychedelics. Although circumstances shifted, I find myself captivated by what could have been.

I’ve been delving into psychedelics in the new trip series on BBC Radio 4. I previously shared my experiences of vivid hallucinations while in a coma from Covid-19. This sparked my curiosity to understand why individuals actively pursue psychedelic experiences, navigate legal challenges, take risks at home, seek healing, and address unmet needs.

There has yet to be a global consensus banning psychedelics. Responding to inquiries by scientist Humphrey Davy, who researched suboxidized oxides in 1799, Humphrey Osmond, coining the term psychedelic in the 1950s, expressed that the study of chemically induced altered states merits rigorous and thoughtful research.

Before the U.S.-led drug war commenced in the 1970s, extensive and promising research into psychedelics as potential treatments was underway, alongside their longstanding use in sacred and ritual contexts by Indigenous cultures. Unfortunately, rather than permitting this exploration, it was driven underground, leaving many to view substances such as fungi and plants, or their lab-created variants, as otherworldly. This otherness surprised me.

Currently, psychedelic research is investigating their therapeutic potential for conditions like depression, addiction, PTSD, eating disorders, dementia, and intergenerational trauma, gaining momentum globally. Studies explore their possible use in extending the recovery window following strokes, enhancing rehabilitation, and even unraveling the nature of consciousness.

Conversations with researchers who meticulously examine substances like psilocybin and DMT in clinical environments feel worlds apart from the psychedelic narratives prevalent in popular culture. These molecules profoundly and enduringly influence our minds and perceptions. It’s perplexing how we opted to stifle a broader inquiry and obstruct our brightest minds from discovering their true potential.

Today’s discussions among researchers are as engaging as they come, yet I can’t help but linger on the “what if?” In light of the global mental health crisis, governments and health systems are eager for new treatment alternatives. Public funding is dwindling and faces threats in many areas, while large corporations driven by profit show substantial interest in the accessibility of new therapies. Changes are happening rapidly.

Examining humanity’s history with psychedelic substances reveals a narrative marked by significant self-inflicted wounds. Ultimately, the funds for the outsight initiative never materialized, leading to a drastically different chapter in history. The war on drugs has stalled research across numerous substances for decades and continues to cast a shadow today.

The narratives surrounding these substances serve as warnings. Politics should never obstruct scientific breakthroughs. In light of today’s world, it feels like an urgent moral imperative to safeguard and nurture the conditions necessary for science to thrive. The stakes are too high.